Filing Details

Accession Number:
0000899243-22-028291
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-10 19:05:58
Reporting Period:
2022-08-08
Accepted Time:
2022-08-10 19:05:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787400 Nkarta Inc. NKTX Pharmaceutical Preparations (2834) 474515206
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1853197 Ralph Brandenberger C/O Nkarta, Inc.,
6000 Shoreline Court, Suite 102
South San Francisco CA 94080
Chief Technical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-08 4,367 $0.41 12,167 No 4 M Direct
Common Stock Acquisiton 2022-08-08 6,886 $3.89 19,053 No 4 M Direct
Common Stock Acquisiton 2022-08-08 340 $4.77 19,393 No 4 M Direct
Common Stock Disposition 2022-08-08 11,593 $15.51 7,800 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-08-08 4,367 $0.00 4,367 $0.41
Common Stock Stock Option (right to buy) Disposition 2022-08-08 6,886 $0.00 6,886 $3.89
Common Stock Stock Option (right to buy) Disposition 2022-08-08 340 $0.00 340 $4.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2028-07-18 No 4 M Direct
37,253 2029-09-05 No 4 M Direct
8,445 2029-05-10 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person at least 30 days prior to the trade date.
  2. This transaction was executed in multiple trades at prices ranging from $15.00 to $16.00. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This stock option is fully vested.
  4. The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on September 5, 2023.
  5. The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on December 6, 2022.